Redcare Pharmacy NV

XTRA:RDC Stock Report

Market Cap: €1.6b

Redcare Pharmacy Future Growth

Future criteria checks 4/6

Redcare Pharmacy is forecast to grow earnings and revenue by 56.3% and 15.8% per annum respectively. EPS is expected to grow by 54.6% per annum. Return on equity is forecast to be 15.8% in 3 years.

Key information

56.3%

Earnings growth rate

54.56%

EPS growth rate

Consumer Retailing earnings growth14.2%
Revenue growth rate15.8%
Future return on equity15.78%
Analyst coverage

Good

Last updated13 Oct 2025

Recent future growth updates

Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Aug 01
Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Recent updates

Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper

Sep 04
Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper

Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Aug 01
Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Jul 13
Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 14
Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Feb 27
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
User avatar

eRx Surge And International Expansion Poised To Elevate Revenue And Profit Margins

Rapid expansion in new markets and tech-driven efficiencies suggest future revenue growth and improved profit margins.

Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Nov 11
Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Apr 21
Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Apr 07
Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Mar 25
Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Feb 13
Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Dec 24
Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Dec 06
Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Sep 07
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Aug 02
Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Jul 17
Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

May 28
Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

May 11
Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Jan 10
We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Sep 25
Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

XTRA:RDC - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20274,23849601178
12/31/20263,574621788
12/31/20252,968-21-2338
6/30/20252,676-35-3644N/A
3/31/20252,528-48-1538N/A
12/31/20242,371-45-2022N/A
9/30/20242,227-25-1131N/A
6/30/20242,128-9-833N/A
3/31/20241,987-10038N/A
12/31/20231,799-122361N/A
9/30/20231,595-16-240N/A
6/30/20231,404-45-1333N/A
3/31/20231,272-65-59-9N/A
12/31/20221,204-78-83-29N/A
9/30/20221,165-110-68-16N/A
6/30/20221,118-105-481N/A
3/31/20221,081-91-406N/A
12/31/20211,060-74-3212N/A
9/30/20211,037-39-1435N/A
6/30/20211,038-29-2827N/A
3/31/20211,020-18-1735N/A
12/31/2020968-17-3618N/A
9/30/2020895-15-56-19N/A
6/30/2020827-20-43-19N/A
3/31/2020758-27-38-16N/A
12/31/2019701-36-45-31N/A
9/30/2019660-41-25-11N/A
6/30/2019621-40-22-10N/A
3/31/2019584-40N/A-26N/A
12/31/2018540-34N/A-15N/A
9/30/2018481-31N/A-31N/A
6/30/2018415-28N/A-24N/A
3/31/2018351-24N/A-17N/A
12/31/2017284-21N/A-23N/A
9/30/2017244-22N/A-11N/A
6/30/2017222-20N/A-16N/A
3/31/2017200-20N/A-14N/A
12/31/2016177-18N/A-17N/A
9/30/2016159-13N/A-5N/A
6/30/2016147-13N/A-5N/A
3/31/2016136-12N/A-7N/A
12/31/2015126-11N/A-9N/A
12/31/201485-5N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).

Earnings vs Market: RDC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RDC is expected to become profitable in the next 3 years.

Revenue vs Market: RDC's revenue (15.8% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: RDC's revenue (15.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RDC's Return on Equity is forecast to be low in 3 years time (15.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/24 16:44
End of Day Share Price 2025/10/24 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Redcare Pharmacy NV is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard SchwarzBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Alvira RaoBarclays